Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Recently, the National Institutes of Health (NIH)'s removal of genetic data about the COVID-19 virus from its archive was brought into the spotlight.
Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look.
The growth of fibril tips is thought to be the ‘Achilles’ heel’ of the process.
Zabdeno, a two-dose heterologous vaccine, was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants.
A patient treated with Astellas Pharma’s experimental gene therapy for patients with X-linked Myotubular Myopathy (XLMTM) has died after a serious adverse event following treatment.
South San Francisco-based Walking Fish started the week off strong by announcing its closing of a $50 million Series A financing round on Monday.
This newfound ability to take tumor cells directly from a patient and incorporate them into a more clinically accurate glioblastoma model could lead to greater patient personalization in cancer therapeutics.
Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.
Bolt Biotherapeutics was anything but quiet this summer.
Dr. Scott Gottlieb estimated that a vaccine for the 5-11-year-old age group could be available by Halloween – in a best-case scenario.
In a recent multinational survey, healthcare providers expressed the belief that immunotherapy will improve outcomes for patients with earlier-stage cancers.
The Phase II study showed enhanced immune memory response to the virus in 96% of vaccinated subjects, all of whom were exposed to an environment dominated by the delta variant.